The Strategic Research Agenda of the LifeTime Initiative is a shared vision of more than 100 institutions and medical centres, 80 private companies, patient organisations and European scientific societies. This research roadmap makes recommendations for investments and research programmes to address main clinical challenges. LifeTime Strategic Research Agenda is a modular strategy document for flexible implementation within existing regional, national and European funding programmes, either as large research initiatives or for smaller, more specific research and innovation programmes, intended at both public and private research funders.
The implementation of the proposed Science and Technology Roadmap will enable to detect and intercept diseases earlier and more efficiently with a cell-based and patient-centered approach and provide effective therapeutic treatments for chronic inflammatory and cardiovascular diseases, neurological conditions and cancer. Applying this approach to key medical challenges will improve the quality of the European citizen’s life and boost the European economy and science.
- Strategic Research Agenda
- Article: LifeTime and improving European healthcare through cell-based interceptive medicine
LifeTime aims to better understand how diseases start and progress in the human body. The main goal for the initiative is to improve European healthcare through cell-based medicine by tracking, understanding and targeting human cells and intercepting disease development at its earliest stages when cells can still be redirected to a healthy life trajectory.
LifeTime is one of the six preparatory actions of the European Commission selected in 2018 that address major technological and societal challenges in the areas of ICT, health and energy. The project aims to develop and integrate several breakthrough technologies including single-cell multi-omics and imaging, machine learning and AI, and personalised disease models such as organoids.
The LifeTime Consortium includes preeminent European laboratories developing multi-omic and bioimaging technologies, institutions developing the required computational technologies and infrastructure, acknowledged laboratories in the field of organoids, bioethicists and a core group of leading clinician scientists.